Antibiotic Resistance of Helicobacter pylori in Eastern China: An Updated Multicenter Cross‐Sectional Surveillance Study From 2022 to 2025
Helicobacter · 2026-09 · 31 (5)
DOI: 10.1111/hel.70170 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Helicobacter, online erschienen am 21.10.2026. Verfasst von Shihan Xu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The National Clinical Research Center for Digestive Diseases, Changhai Hospital, Naval Medical University, Shanghai, …. Hauptthemen laut MEDLINE: Helicobacter pylori, Anti-Bacterial Agents, Helicobacter Infections, Drug Resistance, Bacterial. Die Arbeit nennt 33 Literaturangaben. Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project, National Natural Science Foundation of China, Postdoctoral Fellowship Program of CPSF.
Abstract (Originalsprache)
Background
Rising Helicobacter pylori antibiotic resistance compromises efficacy of empirical eradication therapies. This study aimed to provide updated, region‐specific resistance data in Eastern China to guide empirical treatment strategies.
Methods
A multicenter, cross‐sectional study was conducted across 30 institutions in Eastern China from 2022 to 2025. Susceptibility to six antibiotics was evaluated using the Kirby‐Bauer disk diffusion method.
Results
A total of 1088 H. pylori isolates from gastric biopsies were analyzed. Resistance rates were exceptionally high for metronidazole (93.8%), clarithromycin (71.0%), and levofloxacin (61.2%), whereas resistance to amoxicillin, furazolidone, and tetracycline remained universally low (< 1%). Multidrug resistance (MDR) was highly prevalent at 80.0%. However, resistance to metronidazole, levofloxacin, and clarithromycin showed decreasing trends over the study period.
Interpretation
Given the alarming resistance levels, empirical use of clarithromycin‐ and levofloxacin‐based regimens should be approached with caution in Eastern China. Where universal susceptibility testing is not accessible, there is an urgent need to explore and validate novel, effective empirical eradication regimens and to establish sustained regional resistance surveillance networks to dynamically refine H. pylori management strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, The National Clinical Research Center for Digestive Diseases, Changhai Hospital, Naval Medical University, Shanghai, China.
- National Key Laboratory of Immunity and Inflammation, Naval Medical University, Shanghai, China.
- China Center for Helicobacter Pylori Molecular Medicine, Shanghai, China.
ORCID-Profile: Yifan Qiu, Jiayue Wang, Xianzhu Zhou, Huiyun Zhu, Yiqi Du
Förderung
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- National Natural Science Foundation of China
- Postdoctoral Fellowship Program of CPSF
- Open Research Project of Shanghai Key Laboratory
Zitieren
APA
Xu, S., Qiu, Y., Wang, J., Wang, C., Zhou, X., Zhu, H., Zhu, W., Xie, P., Shen, L., Huang, H., Zhao, X., Gao, H., Li, Z., & Du, Y. (2026). Antibiotic Resistance of Helicobacter pylori in Eastern China: An Updated Multicenter Cross‐Sectional Surveillance Study From 2022 to 2025. Helicobacter, 31(5). https://doi.org/10.1111/hel.70170
Vancouver
Xu S, Qiu Y, Wang J, Wang C, Zhou X, Zhu H, et al. Antibiotic Resistance of Helicobacter pylori in Eastern China: An Updated Multicenter Cross‐Sectional Surveillance Study From 2022 to 2025. Helicobacter. 2026;31(5). doi:10.1111/hel.70170
BibTeX
@article{Xu2026,
author = {Xu, Shihan and Qiu, Yifan and Wang, Jiayue and Wang, Chanjuan and Zhou, Xianzhu and Zhu, Huiyun and Zhu, Wenbo and Xie, Pei and Shen, Liting and Huang, Huabing and Zhao, Xintong and Gao, Hengjun and Li, Zhaoshen and Du, Yiqi},
title = {Antibiotic Resistance of Helicobacter pylori in Eastern China: An Updated Multicenter Cross‐Sectional Surveillance Study From 2022 to 2025},
journal = {Helicobacter},
year = {2026},
volume = {31},
number = {5},
doi = {10.1111/hel.70170}
}
EUVIMED